France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has revealed that it has signed an agreement to fully acquire Qunol, a US-based health and wellness brand. This strategic move is aimed at bolstering Sanofi’s Consumer Healthcare (CHC) unit, enhancing its presence in the consumer health sector.
Expanding into the VMS Segment with Qunol
Sanofi has set its sights on Qunol’s prowess in the vitamin, mineral, and supplements (VMS) segment, which is recognized as one of the largest and fastest-growing areas within the US consumer health market. Qunol is known for its offerings of CoQ10 for heart health and Tumeric for joint health, catering to the health-conscious consumer base. The brand has been experiencing double-digit growth and is already a profitable entity. The acquisition is anticipated to be completed by the third quarter of 2023.
Enhancing Sanofi’s Portfolio and Market Reach
With this acquisition, Sanofi is poised to expand its product portfolio and market reach within the VMS segment. Qunol’s established reputation and product offerings align with Sanofi’s goal to provide consumers with a diverse range of health and wellness solutions. The deal is expected to contribute positively to Sanofi’s CHC unit, further solidifying the company’s position in the global consumer healthcare market.-Fineline Info & Tech
